Introduction {#s1}
============

Q fever, a zoonosis distributed worldwide, is caused by infection with the obligate intracellular microorganism *Coxiella burnetii* \[[@B1]\]. The primary animal reservoirs include cattle, sheep, and goats, and the major transmission route is human inhalation of aerosols or ingestion of unpasteurized dairy products contaminated with feces, urine, or reproductive tissues of infected animals. The clinical presentation of Q fever includes acute and chronic forms \[[@B2]\]. Acute Q fever presents with asymptomatic infection or influenza-like symptoms with various degrees of pneumonia or hepatitis. Culture-negative infective endocarditis is the major presentation of chronic Q fever \[[@B2]\]. During the largest outbreak of Q fever in the Netherlands, pneumonia (61.5%) was the most common presentation, and hepatitis accounted for only 0.4% \[[@B3]\].

*Mycoplasma pneumoniae* and *Chlamydophila pneumoniae* are common atypical pathogens of community-acquired pneumonia \[[@B4]\]. Due to a laborious and expensive culture procedure, serological assessment of antibodies is widely used to diagnose *M. pneumoniae* \[[@B5]\] and *C. pneumoniae* \[[@B6]\], with microimmunofluorescence (MIF) as the recommended method. However, because MIF is a time-consuming procedure and requires an experienced operator, the enzyme-linked immunosorbent assay (ELISA) has become the most commonly used method in clinical practice.

Because culture of *C. burnetii* is a laborious procedure and must be performed in a biosafety level 3 laboratory, serological assessment of antibodies against *C. burnetii* has become the gold-standard method for clinical diagnosis of Q fever. However, serological cross-reactivity with other intracellular pathogens, including *Bartonella* species \[[@B7],[@B8]\], *Legionella micdadei* \[[@B9]\], *Rickettsia* species \[[@B10]\], *Chlamydophila* species \[[@B11]\], *Mycoplasma pneumoniae* \[[@B10]\], cytomegalovirus \[[@B10]\], and Epstein-Barr virus \[[@B10]\], has been reported in Q fever patients. Recently, a case of acute Q fever masquerading as *M. pneumoniae* pneumonia was reported \[[@B12]\]. In clinical practice, we have found several cases of acute Q fever that were serologically positive for *M. pneumoniae* or *C. pneumoniae* IgM before the final results of acute Q fever examinations were available. This finding indicates that patients can be misdiagnosed as atypical pneumonia if they are not tested for Q fever.

The aim of this study was to investigate the seroprevalence of antibodies against *M. pneumoniae* and *C. pneumoniae*, the two most common pathogens of atypical pneumonia, in patients with acute Q fever.

Methods {#s2}
=======

Selection of study cases {#s2.1}
------------------------

Because acute Q fever, scrub typhus (caused by *Orientia tsutsugamushi*), and murine typhus (caused by *Rickettsia typhi*) are the most common rickettsioses in Taiwan, and because they are difficult to differentiate from each other by clinical manifestations \[[@B13]\], cases confirmed for the 3 diseases were included in the investigation. From April 2004 to December 2009, a total of 166 cases of acute Q fever, scrub typhus, and murine typhus were diagnosed and confirmed by the Centers for Diseases Control of Taiwan (Taiwan CDC) at E-Da hospital. Among them, the sera of 160 cases were available for study. To clarify the seroprevalence of each disease, 5 previously published cases of acute Q fever and scrub typhus co-infections were excluded \[[@B14]\]. Finally, the sera (acute or convalescent phase) of 155 cases (102 acute Q fever, 39 scrub typhus, and 14 murine typhus) were included in the study. Among them, 135 cases (89 acute Q fever, 34 scrub typhus, and 12 murine typhus) had paired sera (acute and convalescent phase) for investigating the rates of antibody seroconversion.

Ethics Statement {#s2.2}
----------------

This study was approved by the Ethics Committee of the E-Da Hospital (EMRP-097-117). The committee waived the need for written informed consent because the demographic information and clinical data were retrospectively recorded, and all of the data were collected anonymously.

Clinical characteristics and data collection {#s2.3}
--------------------------------------------

The demographic information, clinical manifestations, and results of laboratory and imaging examinations of the included cases were obtained retrospectively by medical chart review and were recorded using an anonymous case record form.

Confirmatory diagnosis of acute Q fever, scrub typhus, and murine typhus {#s2.4}
------------------------------------------------------------------------

Serological tests for the presence of specific antibodies against *C. burnetii*, *O. tsutsugamushi*, and *R. typhi* were performed using an indirect immunofluorescence antibody assay (IFA) in the contract laboratory of the Taiwan CDC, as previously described \[[@B13]\]. Acute Q fever was diagnosed either by an anti-phase II antigen IgG titer of ≥ 1:320 and an anti-phase II antigen IgM titer of ≥ 1:80, a four-fold or greater increase of anti-phase II antigen IgG titer in paired sera, or by blood that tested positive for *C. burnetii* DNA by polymerase chain reaction (PCR) \[[@B15]\]. Scrub typhus and murine typhus were diagnosed by a specific antibody titer of IgM ≥ 1:80, a four-fold or greater rise of IgG titer in paired sera, or by blood that tested positive for *O. tsutsugamushi* and *R. typhi* DNA by PCR, respectively.

Detection of serum antibodies against *Mycoplasma pneumoniae* and *Chlamydophila pneumoniae* {#s2.5}
--------------------------------------------------------------------------------------------

Serum was the residual specimen obtained for the diagnosis-related purposes of rickettsioses for the Taiwan CDC, and it was stored at -80°C until analysis. The serum IgG and IgM antibodies against *M. pneumoniae* and *C. pneumoniae* were detected using commercially available ELISA kits of *M. pneumoniae* IgG (MYCG0350)/IgM (MYCM0350) and *C. pneumoniae* IgG (CHLG0510)/IgM (CHLM0510) (ELISA kits, NovaLisa™, NovaTec Immundiagnostica GmbH, Germany), respectively. These kits were used for the detection of serum *M. pneumoniae* and *C. pneumoniae* IgG or IgM in clinical practice at E-Da Hospital. To validate the results, a second commercial ELISA kit for the detection of *M. pneumoniae* IgG (SeroMP^TM^ IgG)/IgM (SeroMP^TM^ IgM) and *C. pneumoniae* IgG (SeroCP^TM^ IgG)/IgM (SeroCP^TM^ IgM) (ELISA kits, Savyon Diagnostics, Ashdod, Israel) was used. All of the procedures and the interpretation of antibody determinations were performed according to the manufacturer\'s instructions, and each examination was performed in duplicate.

Statistical analysis {#s2.6}
--------------------

Categorical variables were analyzed using the Chi-square or Fisher's exact test where appropriate. Continuous variables were analyzed using Student's t-test. All *p* values were two-tailed, and a *p* value \<0.05 was considered to be statistically significant. The data were analyzed with SPSS software for Windows (Release 15.0; SPSS, Chicago, IL).

Results {#s3}
=======

Overall status of *M. pneumoniae* and *C. pneumoniae* IgG/IgM in acute Q fever, scrub typhus, and murine typhus {#s3.1}
---------------------------------------------------------------------------------------------------------------

The serum IgG or IgM results of *M. pneumoniae* and *C. pneumoniae* in the 155 cases using the first ELISA kits are shown in [Table 1](#pone-0077640-t001){ref-type="table"}. In acute or convalescent phase sera, 62 (40.0%) and 43 cases (27.7%) had *M. pneumoniae* IgM and *C. pneumoniae* IgM, respectively. The monthly distribution of serum positive cases of *M. pneumoniae* IgM is shown in [Figure 1](#pone-0077640-g001){ref-type="fig"}, and they reached peaks in March, August, and December. [Figure 2](#pone-0077640-g002){ref-type="fig"} illustrates the age distribution of the serum positive cases of *M. pneumoniae* IgM, and it was highest for those aged between 40 and 59 years old. The positivity rates of *M. pneumoniae* IgM in the acute (13.9%, 0%, and 0%, *p*=0.012), convalescent (58.9%, 8.8%, and 0%, *p*\<0.001), and acute or convalescent phases (57.8%, 7.7%, and 0%, *p*\<0.001) of acute Q fever were significantly higher than scrub typhus or murine typhus ([Table 1](#pone-0077640-t001){ref-type="table"}). In contrast, the positivity rates of *M. pneumoniae* IgG and *C. pneumoniae* IgG/IgM were not different between the 3 diseases. To further investigate the seroconversion of *M. pneumoniae* and *C. pneumoniae* antibodies at the acute and convalescent phases, the 135 patients with available paired sera were analyzed, and the results are shown in [Table 2](#pone-0077640-t002){ref-type="table"}. The seroconversion rate of *M. pneumoniae* IgM in acute Q fever was significantly higher than scrub typhus or murine typhus (50.6%, 8.8%, and 0%, *p*\<0.001). However, the seroconversion rates of *M. pneumoniae* IgG and *C. pneumoniae* IgG/IgM were not different. Among the 56 acute Q fever patients with serum *M. pneumoniae* IgM, only 2 (3.6%) and 16 (28.6%) had 4-fold increases of IgG and IgG seroconversion, respectively ([Table 3](#pone-0077640-t003){ref-type="table"}). Taken together, only the positivity and seroconversion rates of *M. pneumoniae* IgM in acute Q fever were significantly higher than scrub typhus or murine typhus.

10.1371/journal.pone.0077640.t001

###### The results of all available sera tested for *Mycoplasma pneumoniae* and *Chlamydophila pneumoniae* IgM and IgG antibodies^[**a**](#ngtab1.1){ref-type="table-fn"}^ in patients with acute Q fever, scrub typhus, and murine typhus.

  Positive antibodies in the acute or convalescent phase                Acute Q fever (N=102)   Scrub typhus (N=39)   Murine typhus (N=14)   Total (n=155)    *p* ^f^
  --------------------------------------------------------------------- ----------------------- --------------------- ---------------------- ---------------- ---------
  *Mycoplasma pneumoniae* IgM^[b](#ngtab1.2){ref-type="table-fn"}^                                                                                            
  Acute or convalescent phase                                           59/102 (57.8)           3/39 (7.7)            0/14 (0)               62/155 (40.0)    \<0.001
  Acute phase                                                           14/101 (13.9)           0/39 (0)              0/13 (0)               14/153 (9.2)     0.012
  Convalescent phase                                                    53/90 (58.9)            3/34 (8.8)            0/13 (0)               56/137 (40.9)    \<0.001
  *Mycoplasma pneumoniae* IgG^[c](#ngtab1.3){ref-type="table-fn"}^                                                                                            
  Acute or convalescent phase                                           72/102 (70.6)           22/39 (56.4)          9/14 (64.3)            103/155 (66.5)   0.274
  Acute phase                                                           51/101 (50.5)           14/39 (35.9)          6/13 (46.2)            71/153 (46.4)    0.308
  Convalescent phase                                                    63/90 (70.0)            17/34 (50.0)          7/13 (53.8)            87/137 (63.5)    0.092
  *Chlamydophila pneumoniae* IgM^[d](#ngtab1.4){ref-type="table-fn"}^                                                                                         
  Acute or convalescent phase                                           26/102 (25.5)           11/39 (28.2)          6/14 (42.9)            43/155 (27.7)    0.357
  Acute phase                                                           11/101(10.9)            6/39 (15.4)           2/13 (15.4)            19/153 (12.4)    0.671
  Convalescent phase                                                    22/90 (24.4)            10 /34(29.4)          6/13 (46.2)            38/137 (27.7)    0.279
  *Chlamydophila pneumoniae* IgG^[e](#ngtab1.5){ref-type="table-fn"}^                                                                                         
  Acute or convalescent phase                                           67/102 (65.7)           31/39 (79.5)          11/14 (78.6)           109/155 (70.3)   0.257
  Acute phase                                                           47/101 (46.5)           23/39 (59.0)          8/13 (61.5)            78/153 (51.0)    0.326
  Convalescent phase                                                    55/90 (61.1)            26/34 (76.5)          10/13 (76.9)           91/137 (66.4)    0.197

Tested by ELISA (NovaTec Immundiagnostica GmbH, Germany).

Positive threshold for *M. pneumoniae* IgM is \> 11 NTU. The positive values ranged from 11.3 to 46.9 (median=15.6) NTU.

Positive threshold for *M. pneumoniae* IgG is \> 11 NTU. The positive values ranged from 11.1 to 47.9 (median=17.0) NTU.

Positive threshold for *C. pneumoniae* IgM is \> 11 NTU (NovaTec-Units). The positive values ranged from 11.1 to 36.2 (median=15.7) NTU.

Positive threshold for *C. pneumoniae* IgG is \> 11 NTU. The positive values ranged from 11.1 to 63.1 (median=20.3) NTU.

Chi-square or Fisher's exact test between acute Q fever, scrub typhus, and murine typhus.

![Monthly distribution of 62 cases with either acute or convalescent phase *Mycoplasma pneumoniae* IgM sera, 155 cases of acute Q fever (59 of 102 cases, 57.8%), scrub typhus (3 of 39 cases, 7.7%), and murine typhus (0 of 14 cases, 0%).](pone.0077640.g001){#pone-0077640-g001}

![Age distribution of 62 cases with either acute or convalescent phase *Mycoplasma pneumoniae* IgM sera, 155 cases of acute Q fever (59 of 102 cases, 57.8%), scrub typhus (3 of 39 cases, 7.7%), and murine typhus (0 of 14 cases, 0%).](pone.0077640.g002){#pone-0077640-g002}

10.1371/journal.pone.0077640.t002

###### The results of paired sera tested for *Mycoplasma pneumoniae* and *Chlamydophila pneumoniae* IgM and IgG antibodies^[**a**](#ngtab2.1){ref-type="table-fn"}^ in patients with acute Q fever, scrub typhus, and murine typhus.

  Antibodies in the acute and convalescent phase                        Acute Q fever (N=89)   Scrub typhus (N=34)   Murine typhus (N=12)   Total (N=135)   *p* ^f^
  --------------------------------------------------------------------- ---------------------- --------------------- ---------------------- --------------- ---------
  *Mycoplasma pneumoniae* IgM^[b](#ngtab2.2){ref-type="table-fn"}^                                                                                          
  Seroconversion                                                        45 (50.6)              3 (8.8)               0 (0)                  48 (35.6)       \<0.001
  Seroreversion                                                         3 (3.4)                0 (0)                 0 (0)                  3 (2.2)         0.668
  Both positive                                                         8 (9.0)                0 (0)                 0 (0)                  8 (5.9)         0.151
  Both negative                                                         33 (37.1)              31 (91.2)             12 (100)               76 (56.3)       \<0.001
  *Mycoplasma pneumoniae* IgG^[c](#ngtab2.3){ref-type="table-fn"}^                                                                                          
  Seroconversion                                                        21 (23.6)              8 (23.5)              2 (16.7)               31 (23.0)       0.950
  Seroreversion                                                         1 (1.1)                2 (5.9)               2 (16.7)               5 (3.7)         0.018
  Both positive                                                         42 (47.2)              9 (26.5)              4 (33.3)               55 (40.7)       0.093
  Both negative                                                         25 (28.1)              15 (44.1)             4 (33.3)               44 (32.6)       0.245
  *Chlamydophila pneumoniae* IgM^[d](#ngtab2.4){ref-type="table-fn"}^                                                                                       
  Seroconversion                                                        15 (16.9)              5 (14.7)              4 (33.3)               24 (17.8)       0.372
  Seroreversion                                                         3 (3.4)                1 (2.9)               0 (0)                  4 (3.0)         0.999
  Both positive                                                         7 (7.9)                5 (14.7)              2 (16.7)               14 (10.4)       0.313
  Both negative                                                         64 (71.9)              23 (67.6)             6 (50.0)               93 (68.9)       0.287
  *Chlamydophila pneumoniae* IgG^[e](#ngtab2.5){ref-type="table-fn"}^                                                                                       
  Seroconversion                                                        19 (21.3)              8 (23.5)              2 (16.7)               29 (21.5)       0.947
  Seroreversion                                                         7 (7.9)                3 (8.8)               0 (0)                  10 (7.4)        0.776
  Both positive                                                         35 (39.3)              18 (52.9)             7 (58.3)               60 (44.4)       0.240
  Both negative                                                         28 (31.5)              5 (14.7)              3 (25.0)               36 (26.7)       0.160

Tested by ELISA (NovaTec Immundiagnostica GmbH, Germany).

Positive threshold for *M. pneumoniae* IgM is \> 11 NTU (NovaTec-Units). The positive values ranged from 11.3 to 46.9 (median=15.8) NTU.

Positive threshold for *M. pneumoniae* IgG is \> 11 NTU. The positive values ranged from 11.1 to 47.9 (median=17.3) NTU.

Positive threshold for *C. pneumoniae* IgM is \> 11 NTU. The positive values ranged from 11.1 to 36.2 (median=15.8) NTU.

Positive threshold for *C. pneumoniae* IgG is \> 11 NTU. The positive values ranged from 11.1 to 63.1 (median=21.3) NTU.

Chi-square or Fisher's exact test between acute Q fever, scrub typhus, and murine typhus.

10.1371/journal.pone.0077640.t003

###### Four-fold increases and seroconversion of *M. pneumoniae* IgG in acute Q fever with serum *M. pneumoniae* IgM by 2 ELISA kits.

  ELISA kit                                4-fold increase of *M. pneumoniae* IgG   Seroconversion of *M. pneumoniae* IgG
  ---------------------------------------- ---------------------------------------- ---------------------------------------
  NovaTec Immundiagnostica GmbH, Germany   3.6% (2/56)^a^                           28.6% (16/56)^b^
  Savyon Diagnostics, Ashdod, Israel       11.1% (5/45)^c^                          11.1% (5/45)^c^

One of the two patients had seroconversion of *M. pneumoniae* IgG

None of the 16 patients had 4-fold increases of *M. pneumoniae* IgG

All of the 5 patients had 4-fold increases and seroconversion of *M. pneumoniae* IgG

Results of *M. pneumoniae* and *C. pneumoniae* IgG/IgM in acute Q fever with the second ELISA kit {#s3.2}
-------------------------------------------------------------------------------------------------

The second ELISA kits (Savyon Diagnostics, Ashdod, Israel) were used to validate the high seropositivity rate of *M. pneumoniae* IgM found in acute Q fever cases. The results and concordant rates compared to the first ELISA kits are listed in [Table 4](#pone-0077640-t004){ref-type="table"}. These revealed positivity rates of 21% (21/100), 45.3% (39/86), and 49.5% (51/103) during the acute, convalescent, and acute or convalescent phases, respectively. Among the cases with available paired sera, the seroconversion rate of *M. pneumoniae* IgM was 33.3% (28/84). Various degrees of concordant rates were found when compared to the first ELISA kits. The 4-fold increase of IgG and IgG seroconversion in the 45 acute Q fever patients with serum *M. pneumoniae* IgM were both 11.1% ([Table 3](#pone-0077640-t003){ref-type="table"}).

10.1371/journal.pone.0077640.t004

###### The results and concordant rates of *Mycoplasma pneumoniae* and *Chlamydophila pneumoniae* IgM and IgG antibodies in patients with acute Q fever tested by ELISA (Savyon Diagnostics, Ashdod, Israel).

  Antibodies in the acute and/or convalescent phase      Positive number/ tested number (%)      Concordant rates^e^ compared with ELISA kits (NovaTec Immundiagnostica GmbH, Germany)
  ------------------------------------------------------ --------------------------------------- ---------------------------------------------------------------------------------------
  *Mycoplasma pneumoniae* IgM^a^                                                                 
  Acute phase                                            21/100 (21)                             52.4%
  Convalescent phase                                     39/86 (45.3)                            79.5%
  Acute or convalescent phase                            51/103 (49.5)                           72.5%
  Seroconversion                                         28/84 (33.3)                            67.9%
  *Mycoplasma pneumoniae* IgG^b^                                                                 
  Acute phase                                            18/99 (18.2)                            94.4%
  Convalescent phase                                     47/89 (52.8)                            87.2%
  Acute or convalescent phase                            50/102 (49.0)                           88.0%
  Seroconversion                                         30/86 (34.9)                            30.0%
  *Chlamydophila pneumoniae* IgM^c^                                                              
  Acute phase                                            9/97 (9.3)                              55.6%
  Convalescent phase                                     29/86 (33.7)                            27.6%
  Acute or convalescent phase                            34/101 (33.7)                           38.2%
  Seroconversion                                         23/82 (28.0)                            21.7%
  *Chlamydophila pneumoniae* IgG^d^                                                              
  Acute phase                                            57/98 (58.2)                            73.7%
  Convalescent phase                                     52/82 (63.4)                            78.8%
  Acute or convalescent phase                            73/100 (73.0)                           78.1%
  Seroconversion                                         14/80 (17.5)                            35.7%

Positive threshold for *M. pneumoniae* IgM is \> 20 BU/ml). The positive values ranged from 20.6 to 146.3 (median=40.7) BU/ml.

Positive threshold for *M. pneumoniae* IgG is \> 20 BU/ml. The positive values ranged from 20.1 to 163.8 (median=38.7) BU/ml.

Positive threshold for *C. pneumoniae* IgM is \> 1.5 COI. The positive values ranged from 1.51 to 5.25 (median=2.0) COI.

Positive threshold for *C. pneumoniae* IgG is \> 1.1 COI. The positive values ranged from 11.1 to 6.31 (median=2.06) COI.

Concordant rate = number of positive samples by both kits/number of positive samples by each ELISA kit (Savyon Diagnostics, Ashdod, Israel) x 100

Status of *M. pneumoniae* IgM and clinical manifestations of acute Q fever {#s3.3}
--------------------------------------------------------------------------

To investigate the possible clinical differences between acute Q fever with and without serum *M. pneumoniae* IgM, the 102 cases of acute Q fever listed in [Table 1](#pone-0077640-t001){ref-type="table"} were divided into 2 groups according to the results of the *M. pneumoniae* IgM in acute or convalescent phase serum for comparison (59 positive cases \[57.8%\] and 43 negative cases \[42.2%\]). There were no significant differences among demographic data, underlying diseases, or clinical symptoms and signs between the 2 groups of patients ([Table 5](#pone-0077640-t005){ref-type="table"}). It is noteworthy that symptoms possibly associated with atypical pneumonia, such as headache (71.2% vs. 81.4%, *p*=0.255), sore throat (8.5% vs. 16.3%, *p*=0.351), and cough (35.6% vs. 23.3%, *p*=0.199), were not different. In imaging findings, laboratory examinations, and responses to treatment, there were no differences between the patients with and without serum *M. pneumoniae* IgM ([Table 6](#pone-0077640-t006){ref-type="table"}). The rate of chest x-ray abnormalities, possibly suggesting pneumonia, was likewise unchanged (19.3% vs. 9.5%, *p*=0.258). Similarly, no significant differences were found by comparing the same variables listed in [Tables 5](#pone-0077640-t005){ref-type="table"} and [6](#pone-0077640-t006){ref-type="table"} between patients with and without seroconversion of *M. pneumoniae* IgM (data not shown).

10.1371/journal.pone.0077640.t005

###### Differences among demographic data, underlying diseases, and clinical symptoms and signs between acute Q fever patients whose sera were positive and negative for *Mycoplasma pneumoniae* IgM^a^.

  Clinical characteristics                   Negative for *M. pneumoniae* IgM (N=43)   Positive for *M. pneumoniae* IgM (N=59)   Total (N=102)   *p* ^b^
  ------------------------------------------ ----------------------------------------- ----------------------------------------- --------------- ---------
  Demographic data and underlying diseases                                                                                                       
  Male gender                                40 (93.0)                                 55(93.2)                                  95 (93.1)       0.999
  Age (years)^c^                             43.6 ± 11.8                               44.8 ± 12.0                               44.3 ± 11.9     0.602
  HBV or HCV infection^d^                    11 (25.6)                                 21 (35.6)                                 32 (31.4)       0.388
  Liver cirrhosis                            1 (2.3)                                   0 (0)                                     1 (1.0)         0.422
  Hypertension                               4 (9.3)                                   7 (11.9)                                  11 (10.8)       0.757
  Diabetes mellitus                          4 (9.3)                                   3 (5.1)                                   7 (6.9)         0.451
  Congestive heart failure                   0 (0)                                     1 (1.7)                                   1 (1.0)         0.999
  COPD                                       0 (0)                                     1 (1.7)                                   1 (1.0)         0.999
  Malignancy                                 0 (0)                                     2 (3.4)                                   2 (2.0)         0.507
  HIV infection                              1 (2.3)                                   0 (0)                                     1 (1.0)         0.422
  Clinical symptoms and signs                                                                                                                    
  Fever                                      42 (97.7)                                 59 (100)                                  101 (99.0)      0.422
  Chills                                     34 (79.1)                                 50 (84.7)                                 84 (82.4)       0.600
  Headache                                   35 (81.4)                                 42 (71.2)                                 77 (75.5)       0.255
  Sore throat                                7 (16.3)                                  5 (8.5)                                   12 (11.8)       0.351
  Jaundice                                   2 (4.7)                                   3 (5.1)                                   5 (4.9)         0.999
  Cough                                      10 (23.3)                                 21 (35.6)                                 31 (30.4)       0.199
  Nausea or vomiting                         2 (4.7)                                   4 (6.8)                                   6 (5.9)         0.999
  Abdominal pain or discomfort               7 (16.3)                                  6 (10.2)                                  13 (12.7)       0.384
  Diarrhea                                   4 (9.3)                                   5 (8.5)                                   9 (8.8)         0.999
  General weakness                           8 (18.6)                                  5 (8.5)                                   13 (12.7)       0.145
  Arthralgia                                 1 (2.3)                                   2 (3.4)                                   3 (2.9)         0.999
  Myalgia                                    19 (44.2)                                 18 (30.5)                                 37 (36.3)       0.211
  Relative bradycardia^e^                    16 (37.2)                                 32 (54.2)                                 48 (47.1)       0.110

Tested by ELISA (NovaTec Immundiagnostica GmbH, Germany).

Categorical variables were analyzed using the Chi-square or Fisher's exact test as appropriate. Continuous variables were analyzed using Student's t-test.

Presented as the mean value ± standard deviation.

Confirmed by examinations of HBsAg and anti-HCV.

Body temperature ≥ 38.9^o^C and heart rate \< 110/min without medication with calcium blockers, beta-blockers, or anti-arrhythmic agents.

10.1371/journal.pone.0077640.t006

###### Differences among imaging findings, laboratory examinations, and responses to treatment between acute Q fever patients whose sera were positive and negative for *Mycoplasma pneumoniae* IgM^a^.

  Clinical characteristics                               Negative for *M. pneumoniae* IgM (N=43)   Positive for *M. pneumoniae* IgM (N=59)   Total (N=102)   *p* ^b^
  ------------------------------------------------------ ----------------------------------------- ----------------------------------------- --------------- ---------
  Abdominal sonography or computed tomography findings   39 (90.7)                                 56 (94.9)                                                 0.451
  Days from disease onset^c^                             6.8 ± 4.0                                 7.0 ± 3.3                                 6.9 ± 3.6       0.778
  Abnormal                                               18/39 (46.2)                              25/56 (44.6)                              43/95 (45.3)    0.999
  Hepatomegaly or splenomegaly                           15 (38.5)                                 18 (32.1)                                 33/95 (34.7)    0.662
  Hepatomegaly                                           9/39 (23.1)                               13/56 (23.2)                              22/95 (23.2)    0.999
  Splenomegaly                                           12/39 (30.8)                              10/56 (17.9)                              22/95 (23.2)    0.216
  Cholecystitic change                                   6/39 (15.4)                               17/56 (30.4)                              23/95 (24.2)    0.143
  Fatty liver                                            22/39 (56.4)                              28/56 (50.0)                              50/95 (52.6)    0.676
  Chest x-ray                                                                                                                                                
  Days from disease onset^c^                             5.3 ± 3.1                                 5.7 ± 2.7                                 5.5 ± 2.9       0.519
  Abnormal CXR finding                                   4/42 (9.5)                                11/57 (19.3)                              16/99 (15.2)    0.258
  Unilateral infiltration                                2/42 (4.8)                                5/57 (8.8)                                7/99 (7.1)      0.695
  Bilateral infiltration                                 2/42 (4.8)                                6/57 (10.5)                               8/99 (8.1)      0.461
  Pneumonia patch                                        0/42 (0)                                  0/57 (0)                                  0/99 (0)        NC
  Complete blood cell examination                                                                                                                            
  Days from disease onset^c^                             5.1 ± 3.1                                 5.3 ± 2.5                                 5.2 ± 2.7       0.813
  Leukocytosis                                           2 (4.7)                                   2 (3.4)                                   4/102 (3.9)     0.999
  Leukopenia                                             9 (20.9)                                  7 (11.9)                                  16/102 (15.7)   0.273
  Anemia                                                 0 (0)                                     0 (0)                                     0/102 (0)       NC
  Thrombocytopenia                                       30 (69.8)                                 43 (72.9)                                 73/102 (71.6)   0.825
  Liver transaminase                                                                                                                                         
  Days from disease onset^c^                             5.6 ± 3.9                                 5.7 ± 2.6                                 5.6 ± 3.2       0.849
  GPT \> 88                                              23/42 (54.8)                              42/59 (71.2)                              65/101 (64.4)   0.097
  GOT \> 76                                              27/42 (64.3)                              43/58 (74.1)                              70/100 (70.0)   0.377
  GPT \> 44                                              40/42 (95.2)                              58/59 (98.3)                              98/101 (97.0)   0.569
  GOT \> 38                                              41/42 (97.6)                              57/58 (98.3)                              98/100 (98.0)   0.999
  Doxycycline treatment to defervescence \> 3 days       5/35 (14.3)                               10/44 (22.7)                              15/79 (19.0)    0.398

Tested by ELISA (NovaTec Immundiagnostica GmbH, Germany).

Categorical variables were analyzed using the Chi-square or Fisher's exact test as appropriate. Continuous variables were analyzed using Student's t-test.

Presented as the mean value ± standard deviation.

Discussion {#s4}
==========

Various degrees of sensitivity, specificity, and cross-reactivity were reported in several commercially available kits of *M. pneumoniae* \[[@B16]-[@B19]\] and *C. pneumoniae* \[[@B20],[@B21]\], but the sera from rickettsioses were rarely used as controls for the evaluation of specificity \[[@B19]\]. In the present study, 57.8% and 25.5% of acute Q fever, 7.7% and 28.2% of scrub typhus, and 0% and 42.9% of murine typhus cases were serum positive for *M. pneumoniae* IgM and *C. pneumoniae* IgM, respectively ([Table 1](#pone-0077640-t001){ref-type="table"}). The seropositive rates of *M. pneumoniae* IgM in acute Q fever were much higher than the acute infection rates of *M. pneumoniae* as determined by serological studies in healthy adolescents (6.0%) \[[@B22]\], adults with respiratory symptoms (3.3%) \[[@B23]\], and community-acquired pneumonia (CAP) (14.3%-20.0%) \[[@B24],[@B25]\] in Taiwan. The seropositivity rates of *C. pneumoniae* IgM were also higher than the percentage of *C. pneumoniae* pneumonia in CAP in Taiwan (7.1%-13.0%) \[[@B24],[@B25]\]. Accordingly, the high seropositivity rates of *M. pneumoniae* and *C. pneumoniae* IgM in the present study did not result from background seroprevalence. These results had two important impacts. First, in clinical practice, rickettsioses may be misdiagnosed as atypical pneumonia if only *M. pneumoniae* and *C. pneumoniae* antibodies are tested. Second, in the investigation of *M. pneumoniae* and *C. pneumoniae* ELISA kits, the sera from rickettsioses should be included for evaluating specificity and possible false-positivity of the ELISA kits.

Both Q fever pneumonia and *M. pneumoniae* pneumonia belong to atypical pneumonia, but serological studies for one in the other are rare \[[@B10],[@B12],[@B19]\]. A case of Q fever presented with acalculous cholecystitis was reported to have serum *M. pneumoniae* IgM (SeroMP^TM^) \[[@B12]\]. Vardi et al. reported that 4 of 33 (12.1%) acute Q fever cases had serum *M. pneumoniae* IgM \[[@B10]\]. In a study by Beersma et al., 3 of the 12 serological kits for *M. pneumoniae* had false positivity for *M. pneumoniae* IgM in 4 Q fever controls (ImmunoCard^TM^ \[75%, 3/4\], Novum^TM^ \[100%, 4/4\], SeroMP^TM^ \[50%, 2/4\]) \[[@B19]\]. In the clinical setting, possible dual infections of *C. burnetii* and *M. pneumoniae* or *C. pneumoniae* have rarely been reported in studies of CAP \[[@B26],[@B27]\]. In an 11-year study conducted in the Canary Islands, 10% of CAP cases were mixed infections. *C. burnetii* was the most frequently isolated co-pathogen, but the pathogens were not clearly described \[[@B26]\]. In a study in northern Israel, Shibli et al. identified Q fever as the microbiological etiology of 8 CAP cases in which 3 (37.5%) and 2 (25.0%) were combined infections with *C. pneumoniae* and *M. pneumoniae*, respectively \[[@B27]\]. In clinical interpretations, the seropositivity and seroconversion of *M. pneumoniae* IgM suggests a recent infection, which indicates that as many as 50-60% acute Q fever cases could be diagnosed as *M. pneumoniae* infection without testing for Q fever. From the epidemiological perspective, this would underestimate and overestimate the true prevalence of Q fever and *M. pneumoniae* infections, respectively.

Acute Q fever, followed by scrub typhus and murine typhus, is the most common rickettsiosis, and it is an emerging and endemic disease in southern Taiwan \[[@B13]\]. In Taiwan, hepatitis rather than pneumonia is the predominant presentation of acute Q fever \[[@B28],[@B29]\]. In our previous study, although all of the cases of acute Q fever had hepatitis, 19% of them had abnormal chest x-ray findings, and 9.5% had unilateral and 9.5% bilateral infiltration \[[@B29]\]. This result indicated that nearly 20% of acute Q fever cases might be diagnosed and treated as pneumonia based on chest x-ray findings without testing for Q fever. In the present study, 57.8% and 25.5% of acute Q fever cases had serum *M. pneumoniae* IgM and *C. pneumoniae*, respectively ([Table 1](#pone-0077640-t001){ref-type="table"}), and 19.3% of cases with *M. pneumoniae* IgM had abnormalities suggestive of pneumonia by chest x-ray ([Table 6](#pone-0077640-t006){ref-type="table"}). These findings highlight that, before the confirmatory results of Q fever are available or without testing for Q fever, approximately 60% and 25% of cases may be misdiagnosed as *M. pneumoniae* and *C. pneumoniae* infection, respectively. Conversely, acute Q fever may account for a portion of serologically diagnosed *M. pneumoniae* and *C. pneumoniae* pneumonia, and the true prevalence of acute Q fever presenting with pneumonia in southern Taiwan may be underestimated.

Several points suggest that the high seropositivity rate of *M. pneumoniae* IgM in acute Q fever may be due to serological cross-reactivity rather than true *M. pneumoniae* infection. First, in addition to developing auto-antibodies \[[@B10],[@B30],[@B31]\], serological cross-reactivity with other pathogens is common in Q fever, including *M. pneumoniae* \[[@B7]-[@B11]\]. Second, the risk of dual infections of non-zootic (*M. pneumoniae*) and zoonotic (*C. burnetii*) atypical pneumonia is low \[[@B32]\]. Third, the monthly and age distributions ([Figures 1](#pone-0077640-g001){ref-type="fig"} and [2](#pone-0077640-g002){ref-type="fig"}) were not typical for *M. pneumoniae* pneumonia, which generally predominates in autumn among children and young adults \[[@B33]\]. Fourth, the clinical symptoms and chest-x ray findings possibly associated with *M. pneumoniae* pneumonia were not different between acute Q fever patients with and without serum *M. pneumoniae* IgM ([Tables 5](#pone-0077640-t005){ref-type="table"} and [6](#pone-0077640-t006){ref-type="table"}). Fifth, it is unreasonable that patients with acute Q fever rather than scrub typhus or murine typhus tend to contract dual infections with *M. pneumoniae*. From the viewpoint of the immune response to *M. pneumoniae*, despite high seropositivity (57.8%) ([Table 1](#pone-0077640-t001){ref-type="table"}) and seroconversion rates of *M. pneumoniae* IgM (50.6%) ([Table 2](#pone-0077640-t002){ref-type="table"}) in acute Q fever, a high IgG seropositivity rate during the acute phase (50.5%), a low IgG seroconversion rate (23.6%), and various concordant rates between the 2 ELISA kits ([Table 4](#pone-0077640-t004){ref-type="table"}) are not typical serological patterns of acute *M. pneumoniae* infection. Further investigation of acute Q fever patients with *M. pneumoniae* IgM revealed that few had 4-fold increases (3.6% and 11.1%) and IgG seroconversion (28.6% and 11.1%) as measured by the two ELISA kits ([Table 3](#pone-0077640-t003){ref-type="table"}), indicating that the presence of IgM did not result from true infection. However, the hypothesis of cross-reactivity between acute Q fever serum and *M. pneumoniae* IgM ELISA kits requires determination by cross-adsorption studies and Western blot analysis, which require culture and large quantities of *C. burnetii* and *M. pneumoniae* antigens in a professional research laboratory \[[@B7],[@B9],[@B34]\].

This retrospective clinical and serological study has several limitations. We only tested 2 ELISA kits commonly used in Taiwan for the serological diagnosis of *M. pneumoniae* and *C. pneumoniae* infections. Whether a similar phenomenon exists with other kits needs further investigation. The studied cases were mainly distributed across southern Taiwan, and the results require a large-scale study involving other countries to be confirmed. The hypothesis of serological cross-reactivity derived from clinical observations needs further investigation by basic medical research in a professional laboratory.

In conclusion, nearly 60% of acute Q fever cases were serum positive for *M. pneumoniae* IgM by ELISA. However, their clinical manifestations were not different from those that were serum negative for *M. pneumoniae* IgM. In addition, approximately 25% of acute Q fever cases were serum positive for *C. pneumoniae* IgM. Clinicians should be aware of the high seroprevalence of *M. pneumoniae* IgM, particularly using ELISA kits, in acute Q fever. This observation could lead to misdiagnosis, overestimation of the prevalence of *M. pneumoniae* infection, and underestimations of the true prevalence of Q fever pneumonia.
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